Zebinix: new for epilepsy

Zebinix (eslicarbazepine acetate) has been launched as an adjunctive treatment for partial-onset seizures with or without secondary generalisation.

Eslicarbazepine acetate is a carboxamide derivative.

The drug's exact mechanism of action is unknown, but it is suggested that it works by stabilising the inactivated state of voltage-gated sodium channels, preventing their return to the activated state therefore sustaining repetitive neuronal firing.

Zebinix must be added to existing anticonvulsant therapy and the dose increased gradually. Zebinix is licensed for the management of epilepsy in adults; caution should be exercised when managing elderly patients and it is not recommended for use in children.

View Zebinix drug record

Further information: Eisai

To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Logo of the webinar

Cow's Milk Allergy in Practice: free webinar series for UK healthcare professionals

Join us for a short webinar series offering insights...

Close up image of multicoloured capsules

MIMS antidepressants table updated

The MIMS table 'Antidepressants, a guide to switching...

Purple, orange, blue and yellow blood test tubes on a tray.

New advice on vitamin B12 monitoring in patients taking metformin

Patients on metformin treatment with risk factors for...